Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial
Cell Transplantation · 2026-07 · 35
DOI: 10.1177/09636897261469013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Transplantation, online erschienen am 14.07.2026. Verfasst von Juan Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR.China. Hauptthemen laut MEDLINE: Busulfan, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Mitoxantrone. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Medical Research Center Project of Xi’an Jiaotong University.
Abstract (Originalsprache)
To investigate the efficacy and safety of MTBF as conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed or refractory acute myeloid leukemia (R/R AML). We conducted a single-arm prospective clinical trial (NCT06385808). The main outcome was cumulative incidence of relapse (CIR), and the secondary outcomes were progression-free survival (PFS), overall survival (OS), engraftment time, graft-versus-host disease (GVHD), and non-hematological adverse effects. Twenty-four R/R AML patients from the First Affiliated Hospital of Xi’an Jiaotong University were enrolled, and all achieved engraftment. Mucositis was the predominant toxicity and was managed appropriately. The two-year CIR was 10%. The two-year OS and PFS were 78.9 ± 11.1% and 51.2 ± 19.3%, respectively. Two patients experienced relapse, and three patients died of infection. Subgroup analyses demonstrated that maintenance treatment post-transplantation may improve OS. The MTBF regimen for salvage allo-HSCT in R/R AML exhibited notable anti-leukemia activity and tolerable toxicity. (NCT06385808, Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR.China.
ORCID-Profile: Xiaoning Wang
Förderung
- Clinical Medical Research Center Project of Xi’an Jiaotong University
Zitieren
APA
Ren, J., Zhang, T., Wang, Y., Zhu, H., Liu, R., He, P., & Wang, X. (2026). Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial. Cell Transplantation, 35. https://doi.org/10.1177/09636897261469013
Vancouver
Ren J, Zhang T, Wang Y, Zhu H, Liu R, He P, et al. Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial. Cell Transplantation. 2026;35. doi:10.1177/09636897261469013
BibTeX
@article{Ren2026,
author = {Ren, Juan and Zhang, Tongxin and Wang, Yuqi and Zhu, Huachao and Liu, Ruimin and He, Pengcheng and Wang, Xiaoning},
title = {Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial},
journal = {Cell Transplantation},
year = {2026},
volume = {35},
doi = {10.1177/09636897261469013}
}
EUVIMED